Outlook Therapeutics price target lowered to $9 from $50 at BTIG
BTIG lowered the firm’s price target on Outlook Therapeutics (OTLK) to $9 from $50 and keeps a Buy rating on the shares. The ...
Zacks.com on MSN3 天
OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study
Outlook Therapeutics OTLK reported preliminary top-line results from the 90-day non-inferiority NORSE EIGHT clinical study ...
Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial
Final efficacy data expected in January 2025Anticipate resubmission of BLA in calendar Q1 2025ISELIN, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- ...
ophthalmologytimes4 天
AI models offer hope for personalized AMD treatment plans
In a study, a team of Korean researchers developed an AI model using OCT images to predict neovascular AMD treatment outcomes after anti-VEGF injections. The model highlights AI’s potential in ...